Cabaletta Bio (NASDAQ:CABA) Upgraded to "Hold" at Wall Street Zen

robot
Abstract generation in progress

Wall Street Zen upgraded Cabaletta Bio (NASDAQ:CABA) from “strong sell” to “hold” on Sunday. Other analysts have also issued reports, with Guggenheim raising its price target to $16.00 and Morgan Stanley decreasing its target to $13.00, both maintaining “buy” or “overweight” ratings. The company has an average rating of “Moderate Buy” and an average price target of $14.00, with recent insider buying and positive earnings surprise.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin